Perspectives in the management of opportunistic infections in HIV-infected patients: the role of granulocyte colony-stimulating factorCLUMECK, Nathan; GOLD, Jonathan.AIDS (Supplement). 1999, Vol 13, Num 2, issn 1350-2840, 33 p.Conference Proceedings

Overcoming therapeutic challenges : resistance, intolerance, end-points. Satellite symposiumCLUMECK, Nathan; LANGE, J. M.AIDS (London). 1995, Vol 9, issn 0269-9370, 36 p., SUP2Conference Proceedings

Prevention of bacterial infections in patients with advanced HIV infectionMITSUYASU, R.AIDS (Supplement). 1999, Vol 13, Num 2, pp S19-S23, issn 1350-2840Conference Paper

Haematopoietic growth factors as supportive therapy in HIV-infected patientsHERMANS, P.AIDS (London). 1995, Vol 9, pp S9-S14, issn 0269-9370, SUP2Conference Paper

Filgrastim treatment of HIV-infected patients improves neutrophil functionPITRAK, D. L.AIDS (Supplement). 1999, Vol 13, Num 2, pp S25-S30, issn 1350-2840Conference Paper

Granulocyte colony-stimulating factor : its potential role in infectious diseaseHARTUNG, T.AIDS (Supplement). 1999, Vol 13, Num 2, pp S3-S9, issn 1350-2840Conference Paper

HIV disease-related neutropenia : an independent risk factor for severe infectionsHERMANS, P.AIDS (Supplement). 1999, Vol 13, Num 2, pp S11-S17, issn 1350-2840Conference Paper

Drug-resistance patterns of saquinavir and other HIV proteinase inhibitorsROBERTS, N. A.AIDS (London). 1995, Vol 9, pp S27-S32, issn 0269-9370, SUP2Conference Paper

Management of cytomegalovirus diseaseDANNER, S. A.AIDS (London). 1995, Vol 9, pp S3-S8, issn 0269-9370, SUP2Conference Paper

Clinical experience with saquinavirVELLA, S.AIDS (London). 1995, Vol 9, pp S21-S25, issn 0269-9370, SUP2Conference Paper

Correlation between viral load measurements and outcome in clinical trials of antiviral drugsSCHOOLEY, R. T.AIDS (London). 1995, Vol 9, pp S15-S19, issn 0269-9370, SUP2Conference Paper

Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trialsCLOTET, Bonaventura; CLUMECK, Nathan; KATLAMA, Christine et al.Journal of antimicrobial chemotherapy (Print). 2010, Vol 65, Num 11, pp 2450-2454, issn 0305-7453, 5 p.Article

Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral loadDE WIT, Stephane; DELFORGE, Marc; NECSOI, Coca Valentina et al.AIDS (London). 2011, Vol 25, Num 10, pp 1332-1333, issn 0269-9370, 2 p.Article

De l'intérêt d'une vaccination thérapeutique chez des patients infectés par le VIH sous traitement antirétroviralBURNY, Arsene; CLUMECK, Nathan; HERMANS, Philippe et al.Bulletin de l'Académie nationale de médecine. 2006, Vol 190, Num 9, pp 1897-1901, issn 0001-4079, 5 p.Conference Paper

Treatment of a bowenoid papulosis of the penis with local applications of cidofovir in a patient with acquired immunodeficiency syndromeSNOECK, Robert; VAN LAETHEM, Yves; DE CLERCQ, Erik et al.Archives of internal medicine (1960). 2001, Vol 161, Num 19, pp 2382-2384, issn 0003-9926Article

Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less: week 48 phase III analysisMOLINA, Jean-Michel; CLUMECK, Nathan; PEDANT, Karla et al.AIDS (London). 2013, Vol 27, Num 6, pp 889-897, issn 0269-9370, 9 p.Article

When should antiretroviral therapy for HIV be started?PHILLIPS, Andrew N; GAZZARD, Brian G; CLUMECK, Nathan et al.BMJ. British medical journal (International ed.). 2007, Vol 334, Num 7584, pp 76-78, issn 0959-8146, 3 p.Article

Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patientsDE WIT, Stéphane; BOULME, Ronan; POLL, Bénédicte et al.AIDS (London). 2004, Vol 18, Num 17, pp 2330-2331, issn 0269-9370, 2 p.Article

Resistance at Virological Failure Using Boosted Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors As First-Line Antiretroviral Therapy—Implications for Sustained Efficacy of ART in Resource-Limited SettingsHILL, Andrew; MCBRIDE, Angela; SAWYER, A. William et al.The Journal of infectious diseases. 2013, Vol 207, issn 0022-1899, S78-S84, SUP2Article

A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1SAAG, Michael; GOODRICH, James; FÄTKENHEUER, Gerd et al.The Journal of infectious diseases. 2009, Vol 199, Num 11, pp 1638-1647, issn 0022-1899, 10 p.Article

Maraviroc for Previously Treated Patients with R5 HIV-1 InfectionGULICK, Roy M; LALEZARI, Jacob; MONTANA, John B et al.The New England journal of medicine. 2008, Vol 359, Num 14, pp 1429-1441, issn 0028-4793, 13 p.Article

Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001SNOECK, Joke; VAN LAETHEM, Kristel; HERMANS, Philippe et al.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 35, Num 3, pp 279-285, issn 1525-4135, 7 p.Article

The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: The EuroSIDA studyMOCROFT, Amanda; KIRK, Ole; CLUMECK, Nathan et al.Cancer. 2004, Vol 100, Num 12, pp 2644-2654, issn 0008-543X, 11 p.Article

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trialsNELSON, Mark; AMAYA, Gerardo; VANVEGGEL, Simon et al.Journal of antimicrobial chemotherapy (Print). 2012, Vol 67, Num 8, pp 2020-2028, issn 0305-7453, 9 p.Article

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mlARRIBAS, Jose R; HORBAN, Andrzej; MOECKLINGHOFF, Christiane et al.AIDS (London). 2010, Vol 24, Num 2, pp 223-230, issn 0269-9370, 8 p.Article